undamentalytics Newsletter
Sign in

Sutro Biopharma, Inc. balance sheet

At the end of fiscal 2025, Sutro Biopharma, Inc. had total assets of $174m, total liabilities of $306m and shareholders' equity of −$132m. It held $58.1m in cash against $0 of debt.

Balance sheet

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2016Dec 20162017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Cash and equivalents122212552063047691905854
Receivables—226612736946
Total current assets—26210129378219353422343151176
Total assets—41223156394341407471387174194
Accounts payable—33666591083
Deferred revenue (current)—112219155172170116
Total current liabilities—323633304267941327553
Short-term debt—1551—9134———
Long-term debt——109251640———
Total debt01515102525164—00
Total liabilities—4792596289190321343306298
Shareholders' equity−91−1091329833225321715045−132−103
Non-controlling interests and other (assets − liabilities − equity)—103—————————
Shares outstanding————————8m9m17m

Balances at each fiscal year end (quarter end in the quarterly view). Total debt is short- plus long-term borrowings, including lease debt where the company reports it within debt. Where assets do not equal liabilities plus shareholders' equity, the difference (non-controlling interests, redeemable preferred shares) is shown on its own line.

Compare with peers

Head to head: SPRO vs STROEDIT vs STROLXRX vs STRO

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Sutro Biopharma, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Sutro Biopharma, Inc.